Shares of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) are down sharply by 34.29% in pre-market trading, falling to $0.46 per share. This is a notable drop from the previous closing price of $0.70.
The decline follows the company’s announcement of a securities purchase agreement with a single institutional investor to sell 4,354,000 shares of its Class A common stock at $0.40 per share. The gross proceeds from this offering are expected to total approximately $3.0 million, with the transaction anticipated to close on or around July 16, 2025.
